Tech Company Financing Transactions
Azelon Pharmaceuticals Funding Round
On 10/5/2004, Azelon Pharmaceuticals received $7 million in Series A funding from Seaflower Ventures and Vengrowth Asset Management.
Transaction Overview
Company Name
Announced On
10/5/2004
Transaction Type
Venture Equity
Amount
$7,000,000
Round
Series A
Proceeds Purpose
The proceeds from the final tranche of our Series A provide us with the resources to rapidly move Ostabolin-C(TM) into a dose-ranging Phase II clinical trial with a four month treatment duration in approximately 200 patients in early 2005
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
200 Barr Harbor Dr. 400
West Conshohocken, PA 19428
USA
West Conshohocken, PA 19428
USA
Phone
Website
Email Address
Overview
The lead program for the Company, a next-generation PTH analogue (Ostabolin-C(TM) s.c. injection) for the treatment of osteoporosis, recently began a Phase II clinical trial. Approximately 250 patients will receive daily injections of one of four doses of Ostabolin-C(TM) or placebo for four months in 25 centers located in the US and Canada.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joan Lau
Browse more venture capital transactions:
Prev: 10/5/2004: True Commerce venture capital transaction
Next: 10/5/2004: Blacksmith Applications venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs